Engineered immune cells take on tough lymphoma
NCT ID NCT07508605
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new type of cell therapy called CD19/CD20 CAR/TRuC-T for people with B-cell lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 20 adults and primarily check for safety, while also looking at whether the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19/CD20 CAR/TRuC-T cells (a type of immune cell therapy)
What this could lead to
If it works, this could offer a new treatment option for patients whose lymphoma has not responded to other therapies.
What could go wrong
This is a very early (Phase 1/2) and small trial with only 20 participants. The therapy may cause serious side effects, and it is not yet known if it will effectively control the cancer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- CD22 CAR T Cell Trial for Kids with B-Cell Cance NCT04088864
- RN1701 CAR-T for B-Cell Lymphoma Trial (NCT07563543)
- CAR-T Therapy for B-Cell Lymphoma Trial NCT07093086
- Nanobody CAR-T for B-Cell Lymphoma (NCT07546630)
- STP938 for Lymphoma: Phase 1/2 Trial (NCT05463263)
- CY-219 CAR-T for Relapsed/Refractory B-Cell Lymp NCT07539688
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen University General Hospital
RECRUITINGShenzhen, Guangdong, 518055, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact